Researchers find lipid PIP2 regulates SK2 channels, potentially leading to novel treatments for atrial fibrillation.

Researchers at Phoenix and UC Davis Health have identified a lipid, phosphatidylinositol 4,5-bisphosphate (PIP2), as a new target for treating atrial fibrillation (AFib), a common heart rhythm disorder affecting over 12 million people. Their study highlights how PIP2 regulates small-conductance calcium-activated potassium channels (SK2), which are linked to heart failure. These findings could lead to novel treatments for AFib and other cardiac arrhythmias.

6 months ago
6 Articles

Further Reading